Tag Archives: Demonstrates

JBNI’s 100 Percent Herbal Bioprin Formula Demonstrates High Anti-cancer Tumor Efficacy at Dana Farber Cancer Institute / Harvard Medical School

August 11, 2012     No comments

Canyon Park, WA (PRWEB) July 31, 2008

The following press release is provided to Cancer researchers only and is to be used only as data for scientific research purposes.

JBNI today released a Dana-Farber Cancer Institute / Harvard Medical School (DFCI/HMS) anti-tumor activity report regarding Formula 15.3 (Bioprin) by Dr. Beverly A. Teicher’s and her team. The report entitled, “Efficacy of orally administered herb preparations against the EMT-6/Parent Tumor,” clinically documents the effect of JBNI’s all-herbal formula on the “equivalent to human metastatic breast cancer.” The report illustrates the potential of naturally occurring herbs for use in clinical / medical applications.

In the summary by Dr. Marianne Spada, Ph.D., the doctor notes that, “JJ-15.3 shows at the dose of 500mg/kg a TGD of 4.15 plus or minus 0.53, which is much more potent than (common chemotherapeutic agents) Melpahlan (2.3tgd) or Carmustine (2.5tgd), and comparable to radiotherapy or Cysplatin in treatment of metastatic cancer.” Dr. Spada goes on to project, “With higher dose and more frequency than current testing (14 days dose), we might observe much greater TGD than current result even with the current level of herbal concentration.”

A full test result spread sheet was also just released. It is entitled, “Tumor growth delay of Herbal Mixture JJ-15.3 in the EMT-6 Murine Marrary Carcinoma at 500mm cubed.” In it, the total anti-tumor effect when supporting x-ray radiation therapy (1 wk at 300 rads = 4.3tgd) with JBNI’s Formula 15.3 is shown to be 5.15tgd plus or minus 0.61.

When asked about the aggressive nature of 15.3′s effect on cancer cells and potential safety issues, JBNI Investor Relations Manager, Ken Case quoted Dr. Teicher’s report saying, “Formula 15.3 has already been on the market as Bioprin for about 15 years as a relaxant and herbal formula for comfort and ease. It is totally herbal, pesticide free, and 100% natural. Besides, the Dana-Farber Cancer Institute / Harvard document clearly says,’There are no signs of toxicity with this herbal mixture.’”

Calling Formula 15.3 a, “remarkable compound,” Dr. Teicher’s report expresses a desire for further study, “to observe how related organs are responding to delay tumor growth so powerfully without any harm as we see in the current testing.”

The DFCI/HMS report concludes, “Different stages of tumor, tumor preventive tests and other types of metastatic cencer should be further studied with this remarkable compound.”

Inspite of the above findings on Bioprin’s all natural formula that uses strictly pesticide free herbal ingredients, JBNI strictly advises against using Bioprin outside of the care of a Board Certified Physician. A JBNI PR representative, Azim Walli states, “anti-tumor efficacy, even under proven invivo conditions, cannot replace the expertise and experience of a trained cancer specialist’s supervision of time tested FDA approved drugs.”

Official copies of the DFCI/HMS document may be requested from JBNI Inc. located in the biotech community of Canyon Park, Wa.

###







Related Carcinoma Press Releases

Read More

Rush University Study Demonstrates Neuro-protective and Anti-inflammatory Activity of RNS60

July 11, 2012     No comments

Tacoma, WA (PRWEB) March 06, 2012

Researchers from Rush University and Revalesio Corporation will be presenting two studies related to developing novel treatments for neuro-inflammatory disease at The American Society for Neurochemistry Annual Conference (ASN) March 3-7, 2012 in Baltimore, Maryland.

The first presentation demonstrates that Revalesio?s lead product, RNS60, inhibits the production of inflammatory proteins and chemicals in brain cells known as glial cells. The anti-inflammatory and neuro-protective activity of RNS60 is mediated via production of a protein called I?B?, a key regulator of inflammatory activity in brain cells.

The second report demonstrates that RNS60 increases the relative proportion of white blood cells called T-regulatory cells (Tregs) in a rodent model of Multiple Sclerosis (MS). Tregs play a vital role in maintaining a balanced immune response. The study also showed that RNS60 shifts the immune response of lymph node cells from a Th17 and Th1 type to a Th2 type, which is consistent with a disease-modifying activity in this model.

Cumulatively, these data show that RNS60 has the potential to act as a novel immunomodulatory agent both within the central nervous system and in the periphery. These findings are particularly relevant to the potential future treatment of MS and other neuroinflammatory diseases including Parkinson?s disease and Alzheimer?s disease.

About RNS60

Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines, chemokines resulting in decreased inflammation and cell death. RNS60 contains charge-stabilized nanostructures (CSN) that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

About Revalesio Corporation

Revalesio is a pioneering clinical stage biomedical company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world to develop RNS60. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuro-inflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.

###





Read More

CME Outfitters Demonstrates Best in Class at the 37th Annual Alliance for Continuing Education in the Health Professions Conference

July 06, 2012     No comments

Powell, OH (PRWEB) April 25, 2012

CME Outfitters (CMEO), a leading international provider for continuing medical education, is proud to announce findings of demonstrated excellence in a feedback survey among many stakeholders at the annual meeting of the Alliance for Continuing Education in the Health Professions (ACEHP). CME Outfitters authored and produced two poster presentations for this four-day conference. These posters were displayed in the halls of the conference center, allowing conference participants to browse during session breaks.

A compelling poster presented an in-depth look at outcomes data from a recent CMEO activity and the resultant outcomes article entitled “A Simplified Model for Educational Outcomes Measurements (EOMs): Change in Serum Lipid Monitoring Rates in Patients with Bipolar Disorder.” These data demonstrated direct level five performance-based outcomes; the results rose to statistical significance regarding change in clinicians? behavior for serum lipid monitoring in a population at risk for cardiometabolic syndrome. For example, the percentages of patients monitored by clinicians nationwide (in U.S.) who participated in the CME activity increased by 17.8% over 1 year from baseline (p = .00001). Gross, median monitoring rates in the national study group increased from 30% to 80%, and all clinicians at or above the 75th percentile of monitoring rates monitored 100% of their patients after participating. Monitoring rate increases for clinicians in the nationwide learner group were greater among clinicians with higher patient counts. The local study group at the Lindner Center of HOPE increased gross monitoring by 28.0% (from 27.5% to 55.5%), or a 102% increase over baseline rates. The co-sponsors, USF Health and CME Outfitters gratefully acknowledge support from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly USA, LLC, for the ?Change in Serum Lipid Monitoring Rates in Patients with Bipolar Disorder? educational research study and the foundational educational activities upon which the article was based.

CMEO displayed another poster that detailed educational effectiveness and advanced outcomes data. This poster demonstrated that the CME Outfitters 2010 Annual Chair Summit meeting had a statistically significant impact on positive patient health outcomes. The poster was entitled “Ask the Expert Meets Peer-to-Peer: Outcomes from the 3rd Annual Chair Summit ? Master Class for Neuroscience Professional Development. During the outcomes studies, participants were asked if they changed their clinical decision-making processes or any direct patient care as a result of participating in the 3.5-day Chair Summit conference. The responses were overwhelming, with 62% of respondents saying, ?Yes.? USF Health and CME Outfitters also acknowledges support from AstraZeneca, Cephalon, Inc., Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, Lilly USA, LLC, Pfizer, Inc. and Sepracor, Inc. for the ?Outcomes from the 3rd Annual Chair Summit ? Master Class for Neuroscience Professional Development? educational research study and the educational activity upon which it was based.

CMEO received an overwhelmingly positive response from the meeting?s attendees. Participants enjoyed the informative display and congratulated CMEO on their exceptional outcomes analyses, a core competence at the company. Joy Bartnett Leffler, CMEO?s Senior Medical Program Director and Director of Educational Research & Outcomes remarked, ?It is exciting to share such compelling data with our colleagues in the CME community. At CMEO, we work every day to demonstrate that well-designed and thoughtfully executed educational activities can make a difference in the lives of patients. Our collaborators helped us to achieve these significant results. CMEO continues to set the pace for educational outcomes that improve clinical practice?one change at a time.?

CME Outfitters was proud to be accepted as a presenter at the ACEHP this year as well. CMEO Managing Partner, Shari Tordoff, CCMEP, presented during a breakout session on day two of the conference. Ms. Tordoff worked alongside Karen Roy and Dr. Thomas Roth, from University of Michigan on an educational session detailing: Publications in CME: Disseminating the Data to Multiple Audiences. Objectives of this presentation were to allow learners to identify publications opportunities for their own CME program, implement a strategic publications plan targeting both education and medical literature, engage faculty in publications development and harness CME publications for internal CME advocacy. Positive buzz was created around this session as participants were tweeting their approval of Dr. Thomas Roth joining the live presentation via Skype. Participants were impressed not only by the content of the session, but also by the successful fluidity of the presentation with use of modern technology.

CMEO?s leadership in the CME community continued to be highly visible at the annual meeting of the National Association of Medical Education Companies (NAMEC). In addition to receiving the award for Best Practices in Collaboration Among CME Stakeholders and the 2012 Brian P. Russell Exemplary CME Professional, CMEO Managing Partner, Jan Perez, CCMEP who serves as the Chair of the NAMEC Program Committee, facilitated a highly interactive session entitled Developing a Funding Strategy When Multisupport Falls Short. The town hall style discussion was very unique bringing together competitors to share ideas and brainstorm strategies related to managing funding shortfalls for multisupport grants, which is a universal challenge facing medical education companies today. ?We were a little hesitant about the session and concerned that no one would want to give away their secrets, but were overwhelmed by the group?s willingness to share and work together to tackle one of our biggest challenges?, stated Perez.

About CME Outfitters, LLC

CME Outfitters develops and distributes live, recorded, and web-based evidence-based educational activities to thousands of clinicians each year and offers expert accreditation and outcome services for non-accredited organizations. For a complete list of certified activities and more information, visit http://www.cmeoutfitters.com or call 877.CME.PROS (877.263.7767).

About neuroscienceCME

neuroscienceCME.com is an award-winning web portal serving clinicians, educators, and researchers in the neurosciences. Launched in October 2006, neuroscienceCME.com fills an identified gap in online resources for professionals around the world who practice in areas related to psychiatry, sleep disorders, pain, and neurology. The site’s primary mission is to be a central forum for accessing, debating, synthesizing, and implementing the latest findings and best practices in the neurosciences. Visit http://www.neuroscienceCME.com to learn more.

?Improving Clinical Behavior ? One Change at a Time?







Read More

Entelos PhysioLab Demonstrates Predictive Accuracy in Drug Development

June 26, 2012     No comments

San Mateo, CA (PRWEB) June 06, 2012

Entelos, a premier provider of in silico modeling and simulation products and consulting services that help pharmaceutical and consumer product companies make better decisions in their product development process, modeled the mechanistic effects of cholesteryl ester transfer protein (CETP) inhibitors in its cardiovascular PhysioLab platform and predicted unsuccessful outcomes for several class members at the American Heart Association (AHA) annual meeting in 2011. CETP inhibitors have been considered the next promising group of drugs to enhance the effect of statins in the prevention and treatment of abnormal cholesterol profiles and their impact on cardiovascular disease. Entelos? unique modeling process predicted recent clinical trial results demonstrating that these drugs do not provide significant clinical efficacy over that seen with statin therapy alone.

?Drug companies spend billions of dollars annually sponsoring trials that test drug safety and efficacy in humans,? said Shawn O?Connor, president and CEO of Entelos. ?Despite this, fewer than10% of drugs make it from Phase I to launch. Mechanistic modeling is revolutionizing the time and resources required to understand the effects of new drugs, and is simultaneously reducing the risk to humans who participate in clinical studies. Entelos PhysioLab platforms have been providing accurate predictions that have been relied on by world-class collaborators and clients for over 15 years. Our platforms define mechanisms of action and identify biomarkers for patient response ? streamlining or eliminating the need for trial and error clinical studies ? resulting in sizable cost savings, and time-to-market efficiencies.?

Entelos? CV PhysioLab platform has the capability to assess CETP inhibitors in addition to other marketed therapies and novel therapeutic targets for reducing CV risk. The software, a mechanistic computer model of coronary heart disease (CHD) physiology, simulates the cumulative effects of cholesterol metabolism, inflammation and platelet function on plaque growth in the coronary arteries over time through the dynamic modeling of relevant biological pathways. Statistical methodologies are used to relate predicted changes in plaque characteristics to the likelihood of CHD improvement. Such predictions can rapidly be made for approved or novel compounds and drugs in software- created virtual patients and populations, representing the full diversity of patients observed in the clinic. When the detailed effects of three different CETP inhibitors were represented in the model, simulations predicted no significant difference in outcomes between the control and treatment groups, in a typical phase III event trial in thousands of patients over many years. These outcomes closely aligned with those from actual trials. Under other circumstances, the model might have predicted that changes in patient selection could change trial design resulting in better clinical trial outcomes.

Entelos has fully developed platforms in multiple disease areas in addition to Cardiovascular Disease including: Metabolism (with diabetes and obesity), Rheumatoid Arthritis, Hypertension (with heart and kidney failure), Dermatology, Hematology, Infection, Nutrition, and Veterinary Nutrition.

About Entelos

Entelos is an in silico modeling and simulation software and services company delivering predictive technologies reducing risk, time, and cost of product development for pharmaceutical, biotechnology, nutrition and consumer products customers. The Company?s PhysioLab systems biology platforms generate virtual patient populations providing highly predictive analyses to develop safer and more effective drugs, foods and consumer products. Entelos? understanding of patient variability has significant application to the emerging field of personalized medicine. The Company is headquartered in San Mateo, California. For more information, and to see the AHA poster, please visit http://www.entelos.com.

###

Contact:

Wendy Shelton, 650-572-5430

VP, Corporate Communications

shelton(at)entelos.com







Read More

Study demonstrates Biospace med’s 3D x-ray orthopedic imaging system, ‘EOS’, “shows better image quality” than Computed Radiography (CR) while reducing up to 90% of the radiation dose : “EOS represents one of the most significant advances in support of the Image Gently initiative of the Alliance for Radiation Safety in Pediatric Imaging.” Marie Meynadier, Ph.D., CEO, Biospace med

June 07, 2012     No comments


ATLANTA (PRWEB) December 1, 2008

EOS is designed to capture head-to-toe images of patients in a standing, weight-bearing position while reducing up to 90% of the radiation dose compared to a conventional x-ray and up to 1000 times less radiation than a conventional CT scan. Additionally, EOS 3D reconstructions provide remarkable detail, enabling physicians to better diagnose and plan an effective course of treatment.

“While our study involved 50 children and adolescents ranging in age from 11 to 19, EOS can be utilized for patients of all ages,” said Sylvain Desch?nes, Ph.D., a medical physicist at Sainte-Justine Mother and Child University Hospital Center, Montreal, and a principal investigator for the study. “Because EOS provides high-quality images for clinical diagnosis while using considerably less radiation than a conventional x-ray or CT scan, it represents a significant advancement in medical-imaging technology, especially for children with pediatric scoliosis ? a condition involving a curvature of the spine that usually requires repeated x-ray exams during the course of their clinical follow-up.”

“It is well-established that the amount of radiation patients are receiving from medical x-rays is increasing significantly, and unfortunately, this includes children,” added Biospace med CEO, Marie Meynadier, Ph.D. “Published data show an increased cancer risk*, especially among young females who may have a regular need for conventional x-ray monitoring. This is most unacceptable,” said Dr. Meynadier, “because it does not have to be this way. A different approach needs to be taken, especially with children.

“A dose of common sense demands that we do all we can to reduce radiation, and we are extremely proud that EOS is playing a leading role in making this happen,” added Dr. Meynadier. “Indeed, the recent clearance of EOS in the U.S. and Europe is one of the most significant advances that has taken place in support of the Image Gently initiative of the Alliance for Radiation Safety in Pediatric Imaging, whose goal is to change the practice of imaging by increasing awareness of the opportunities to lower radiation dosage in the imaging of children.”

About the EOS Ultra-Low-Dose 3D Orthopedic Imaging System

Recently cleared by the FDA, EOS acquires two simultaneous low-dose planar AP/PA and LAT images, which can be as large as full body. The associated sterEOS workstation allows a review of the images, the production of clinical parameters, and the reconstruction of a 3D image of the adult spine. The company has also developed additional software** to address pediatric spine and a lower extremity package for hip and knee assessment. The workstation software is designed to enable measurements within 3D space, which eliminates errors made from projected planar x-ray images.

About the Alliance for Radiation Safety in Pediatric Imaging

The Alliance is a consortium of professional societies who are concerned about the radiation exposure that children receive when undergoing medical imaging procedures. Currently, 13 societies representing the fields of radiology, pediatrics, medical physics and radiation safety are involved. The Alliance recognizes the often life-saving value of medical imaging. However, techniques used in pediatric imaging may not be?tailored to children’s smaller bodies, resulting in radiation exposures that are greater than necessary. This is especially true for CT scans.

About Biospace med

Biospace med was founded on a unique partnership between Nobel Prize-winning physicist Georges Charpak and a team of biomedical engineers, orthopedic surgeons and radiologists who have developed a complete orthopedic imaging solution. The Company’s lead product, EOS ultra-low-dose 2D/3D x-ray imager, allows full-body imaging of patients in a weight-bearing position that enables global assessment of balance and posture. The Company has corporate headquarters in Atlanta and Paris, an office in Montreal, and is targeting a $ 2 billion orthopedic imaging marketplace. Learn more at http://www.biospacemed.com.


Breast cancer mortality after diagnostic radiography: findings from the U.S. Scoliosis Cohort Study. Morin Doody M, Lonstein JE, Stovall M, Hacker DG, Luckyanov N, Land CE. Spine, 2000 Aug 15;25(16):2052-63. (A retrospective cohort study was conducted in 5573 female patients with scoliosis who were referred for treatment at 14 orthopedic medical centers in the United States. Patients were less than 20 years of age at diagnosis. These data showed that exposure to multiple diagnostic radiographic examinations during childhood and adolescence resulted in a 69% increase in the likelihood of death from breast cancer.)

** sterEOS 3D is currently commercially available in Europe and Canada for spine and is cleared in the US for patients over 16 years of age.







Read More

ChemoCentryx Reports CCX140-B Meets Primary Endpoint and Demonstrates Clinical …

September 17, 2011     No comments

ChemoCentryx Reports CCX140-B Meets Primary Endpoint and Demonstrates Clinical …
This was a multinational, randomized, double-blind, placebo and active-controlled clinical trial in 159 patients with type 2 diabetes on stable doses of metformin. HbA1c was 6.5 to 10% and fasting plasma glucose 135 to 270 mg/dL at study entry. …
Read more on MarketWatch (press release)

Appetite hormone leptin may offer Type 2 diabetes treatment
The hormone leptin, naturally produced by fat cells and long known to play an important role in regulating appetite and fat metabolism, may prove to be successful in treating Type 2 diabetes, a disease that affects more than 21 million people in the …
Read more on UC Davis

Read More
Powered by WordPress | Designed by: best suv | Thanks to toyota suv, infiniti suv and lexus suv